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NGF2002: MORE POWERFUL THAN NGF1951
In 1951, Rita Levi-Montalcini discovered nerve growth-
stimulating factor, later named nerve growth factor (NGF), 
which today is recognized as the paradigm of a whole family of 
neurotrophic proteins, the neurotrophins. Half a century later, 
on 15-19 May, 2002, in Modena, Italy, The 7th International 
Conference on NGF and Related Molecules celebrated this tour 
de force of NGF’s discovery, by presenting the state-of-the-art 
in neurotrophic factor research, including 60 lectures and 75 
posters from world experts in neurotrophobiology, including, 
most notably, Rita Levi-Montalcini herself from Italy, as well 
as E. Shooter, M. Chao, L. Green, E. Johnson Jr, L. Parada, 
B. Hempstead, L. Reichardt and W. Mobley from the USA, 
D. Kaplan and J. Bienenstosk from Canada, H. Thoenen, R. 
Paus and K. Unsicker from Germany, L. Olson, T. Lundeberg 
and C. Ibanez from Sweden, H. Matsuda and A. Nakagawara 
from Japan, M. Fainzilber and P. Lazarovici from Israel, S. 
Lahteinen from Finland, and R. Rush  from Australia.  
    Since the first meeting  held in 1986 in Monterey, USA, 
Members of the International Scientific Committee, E. Shooter 
and R. Bradshaw from USA and R. Rush from Australia, 
succeeded admirably in promoting this biannual meetings, 
which encourages and facilitates the free and sometimes 
provocative expression and exchange of ideas. The Modena 
NGF2002 Conference emphasized the increasing significance 
of neurotrophins and related molecules in a variety of neuronal 
and nonneuronal functions and disorders. Luigi Aloe from 
Rome and Laura Calza from Bologna, functioning as 
Chairman and Vice Chairman, did a superb job of organizing 
the Conference. More than 200 participants were “housed in 
enriched environment” in the Castle of the Doge’s Palace 
that certainly resulted in an increase in the brain levels of 
NGF, BDNF and NT-3 (Mohammed, Huddinge). Further, 
participants’ feeding behavior was provoked by the delicious 
local cuisine, including parmigiano cheese and red wine, that, 
via the gastric hormone cholecystokinin-8 (Tirassa et al, Rome, 
Stockholm; Bucinskaite et al, Stockholm, Rome, Ohtawara) 
and certain probiotics (Bienenstock and Ma, Hamilton), also 
might have contributed to the elevated amount of brain and 
gastrointestinal NGF, respectively. The only gripe among 
some participants was that they seemed to take too seriously 
the recent findings of their colleagues Iannitelli et al (Rome), 
concerning NGF’s ultradian cycle in humans. This work, 
showing that NGF plasma levels are highest in the morning, 
apparently stimulated the organizers to schedule conference 
sessions to begin at 8AM, a brutally early hour, considering 
the many liquid evenings spent in Modena. Note that these 
may induce motion sickness syndrome due to rotation, 
hypergravity-like reactions leading to significantly increased 
expression of NGF in hypothalamus, hippocampus, olfactory 
bulbs and in both frontal and parietal cortex (Santucci et al, 
Rome).       
    The Modena NGF2002 meeting began with the talk of 
the Nobel Laureate Rita Levi-Montalcini on “NGF and the 
neuroscience chess board”. After reviewing the major NGF 
findings, she hypothesized that the role of NGF may be likened 
to that of the “pawn” on the real chess board. She suggested 
that: “In the neuroscience chess board the genes involved 
in functions which were considered in the past of second 
order such as that of the “pawns” of the real chess board, 
program the release of chemical substances, which intervene 
in the complicated nervous and non-nervous functions of all 
vertebrates, from the lowest to the highest phylogenetic level. 
One of these substances is the NGF.”
    The Conference highlighted different aspects of our current 
understanding of neurotrophin-receptor signal transduction 
pathways (Barker, Montreal; Bothwell et al, Seattle; Chao et 
al, New York; Fainzilber et al, Rehovot, Stockholm, Edinburg; 
Johnson Jr et al, St Louis; Kaplan and Miller, Montreal; Rudkin 
et al, Lyon, San Francisco; Carter et al, Nashville, Yokohama; 
Comella et al, Spain; Gentry et al, Nashville; Heerssen et al, 
Boston; Heumann et al, Leipzig; Suzuki et al, Osaka; Kruttgen 
et al, Bern, Stanford; Minichiello et al, Heidelberg, Tubingen, 
Hamburg, Berlin, Monterotondo, Nebraska, Cleveland; 
Friedman et al, New York, Rehovot), including the signaling 
endosome hypothesis (Mobley et al, Stanford; Kruttgen et al, 
Bern, Stanford; Bronfman et al, Rehovot, Göettingen; Zurzolo 
et al, Napoli). Also presented were the synaptotrophic potential 
of NGF and related neurotrophins (Black et al, New Jersey; Lu, 
Bethesda; Tsumoto, Osaka; Kojima et al, Osaka), neurotrophin 
involvement in neuronal stem cell biology (Angelastro et al, 
New York, Gainesville; Calza et al, Bologna; Triaca et al, 
Rome; During et al, Philadelphia, for VEGF; Kessler et al, 
Chicago, Bronx, for BMP-4; Chalazonitis et al, Chicago, 
Bronx, for BMP-2,-4), biological activity of the NGF 
precursor proNGF (Fahnestock et al, Hamilton; Hempstead, 
New York; Yoon et al, Columbus), and nociception- and 
antinociception-associated activity of NGF and/or BDNF 
(Lundeberg, Stockholm; McMahon, London; Merighi et al, 
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Torino, Padova). Receptor signaling by members of the GDNF 
family was also highlighted (Ibanez, Stockholm; Lindahl et al, 
Helsinki, New York; Popsueva et al, Helsinki; Runeberg-Roos 
et al, Helsinki; Tsui-Pierchala et al, St Louis).
NONNEURONAL NGF    
During some 25 years after the discovery of NGF there 
have been few reasons given to indicate that NGF acts on 
nonneuronal cells. Thus, it was remarkable to discover that 
treatment of rats with NGF caused a significant increase in 
the number of mast cells in various tissues. This seminal 
finding, published by Luigi Aloe and Rita Levi-Montalcini in 
Brain Research 1977; 133: 358-366, has triggered the study 
on nonneuronal activities of NGF, particularly, NGF-based 
neuroimmune communication. Such immunotrophic actions of 
NGF, also other neurotrophic factors subsequently discovered, 
opened a novel avenue in the study of neurobiology, namely, 
the basic and clinical neuroimmunology. Thus we witness an 
exciting time in the field of integrative physiology. Accordingly, 
several presentations at the Modena NGF2002 Conference 
dealt with the involvement of various neurotrophins in the 
control of different nonneuronal processes, such as immune, 
inflammatory and allergic reactions (Bracci-Lauiero et al, 
Rome; Lazarovici et al, Jerusalem; Levi-Schaffer et al, 
Jerusalem, Rome; Frossard, Illkirch; Raychaudhuri and 
Raychaudhuri, Palo Alto; Celestino et al, Rome; Renz, 
Marburg; Pignatti et al, Modena), angiogenesis (Madeddu 
et al, Osilo, Rome; Turrini et al, Rome), tissue repair/wound 
healing (Matsuda, Tokyo; Aloe and Lambiase, Rome; Rama 
et al, Rome, Milan; Micera et al, Jerusalem, Rome), and even 
hair growth (Paus, Hamburg; Grim et al, Milwaukee, Prague). 
These findings showed that neurotrophins play important roles 
in the pathobiology of a wide range of seemingly unrelated 
diseases (Table). 
   Also presented at Modena NGF2002 were important new 
findings on the involvement of NGF and related molecules in 
neurological diseases, including Huntington’s disease (Alberch 
et al, Barcelona), multiple sclerosis (Althaus, Göttingen), 
including its models, experimental allergic encephalomyelitis 
Diseases Authors
Bronchial asthma Frossard, Illkirch
  Renz, Marburg
  Braun et al, Hannover, Marburg 
Cutaneous ulcers Aloe and Lambiase, Rome
  Matsuda, Tokyo 
  Manni et al, Florence, Rome, Oristano
  Anand and Sinicropi, London, San Francisco 
Allergic and ulcerative eye disorders Levi-Schaffer et al, Jerusalem, Rome
  Rama et al, Rome, Milan
  Coassin et al, Rome, Milan 
Behcet’s disease Bruscolini et al, Rome
Colitis Bienenstock and Ma, Hamilton 
Hair growth disorders Paus, Hamburg 
Psoriasis Raychaudhuri and Raychaudhuri, Palo Alto 
Breast cancer Bernardini et al, Catania, Jerusalem
Crush syndrome Chiaretti et al, Rome
Atherosclerosis Hempstead, New York 
  Chaldakov et al, Varna, Rome   
Peripheral ischemic vascular disease Madeddu et al, Osilo, Rome
  Turrini et al, Rome
Persistent truncus arteriosus Sieber-Blum et al, Milwaukee, Frederick, Osaka 
Table. NGF and other neurotrophins in nonneurological diseases
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(Genain, San Francisco; Oderfeld-Nowak et al, Warsaw, 
Rome; Zaremba et al, Warsaw, Rome), peripheral neuropathies 
(Anand and Sinicropi, London, San Francisco), inherited 
retinopathy (Amendola and Aloe, Rome), neuroblastoma 
(Nakagawara, Chiba), brain tumors (Antonelli et al, Rome), 
epilepsy (Lahteinen et al, Kuopio; Larmet et al, Strasbourg; 
Tongiorgi et al, Trieste, Ferrara), Alzheimer’s disease (Della 
Valle et al, Bologna, Verona; Tuttle et al, Charlottesville; 
Diamond et al, Hamilton, Montreal), Parkinson’s disease 
(Tuttle et al, Charlottesville; Commissiong et al, Toronto, for 
mesencephalic astrocyte-dervied neurotrophic factor), spinal 
cord injury (Olson, Stockholm; Verhaagen, Amsterdam; Boyd 
et al, Kingston, Saskatoon), traumatic brain injury (Chiaretti 
et al, Rome), and even motion sickness syndrome (Santucci et 
al, Rome), also psychiatric disorders (Fiore and Korf, Rome, 
Groningen), including depression (Angelucci and Mathe, 
Stockholm, Rome; Castren et al, Kuopio).
THERAPEUTIC NGF
Another viewpoint that clearly emerged at the Modena 
NGF2002 Conference was that the administration NGF and/or 
NGF/Trk A or NGF/p75 antagonists to patients or experimental 
animals with at least certain of the above-mentioned diseases, 
are likely to exert important therapeutic benefits. For example, 
Anand from London presented a talk entitled “how can we 
make them work?”, which described ongoing clinical trials 
using rhNGF, rhBDNF, and rhNT-3 in diabetic neuropathy and 
gastrointestinal dysmotility. And, Karen Philpott et al from 
GlaxoSmithKline in Harlow focused on the search for small 
molecules as drugs targeting modulation of neurotrophic factor 
receptor signaling in neurodegenerative disease. Additionally, 
Luigi Aloe’s group from Rome presented important findings 
on the beneficial effects of topically applied NGF in human 
cutaneous and corneal ulcers (effects that are apparently due 
to NGF’s anti-inflammatory and tissue-repairing activities), as 
well as presenting findings on the beneficial effects of topically 
applied NGF in peripheral ischemic vasculopathies (apparently 
due to its angiogenic activity). An additional sub-theme of the 
Conference was that the neurotrophins could act to upregulate 
some hidden actions of drugs that are already in wide clinical 
use. For example, Bernardini et al (Catania, Jerusalem) 
demonstrated that the antiestrogen drug tamoxifen inhibited 
NGF-induced cell proliferation in human breast cancer cell 
line; Angelucci and Mathe (Stockholm, Rome) and Castren et 
al (Kuopio) presented data suggesting that neurotrophins may 
be involved in the therapeutic potential of antidepressant drugs; 
and Giardino et al (Bologna, Milan, Rome, Modena) implicated 
increased expression of NGF and BDNF in the neuroprotecive 
effect of nicergoline (sermion). It is worth reminding here that 
aspirin kept hidden its anti-platelet therapeutic action until the 
discovery of prostanoids; likewise, pentoxifylline revealed its 
anti-TNF/anti-inflammatory potential due to the advancement 
in cytokine research. Then why not look for other “old” drugs 
to disclose their neurotrophic factor-mediated therapeutic 
potential?   
    In effect, the Conference raised many intriguing leads about 
how novel, neurotrophin-targeted therapies could develop in 
the near future. In a similar vein, talks from Oderfeld-Nowak 
et al from Warsaw and Rome, Lazarovici et al from Jerusalem, 
Rehovot and Bazel, and Wekerle from Berlin suggested that the 
secretion of neurotrophins by T-cells invading the CNS (which 
has been dubbed “neuroprotective autoimmunity”) may have 
potential therapeutic implications for neuroimmune diseases 
such as multiple sclerosis. These new findings as well as a 
lot of other valuable data presented at the Conference that 
we unfortunately do not have space to discuss here, left the 
Conference’s participants with the general idea that the actions 
of neurotrophins are complex and diverse, and that they need 
to design many new studies to determine how these agents 
can, under different conditions, both promote and suppress 
various processes mediated by autoimmunity, inflammation, 
and allergy. Overall, this cultivated much a new thinking about 
the therapeutic potentials of various neurotrophic factors. 
CONCLUSION
All the events included in the program of NGF2002 were 
shared by the vital presence of Professor Rita Levi-Montalcini 
herself. As often occurs, the framework of an initial conception 
of the physiological significance of newly discovered molecule 
extends in the light of emerging findings. Clearly, NGF is 
one of the most exciting examples of this intellectual growth 
process. Conceived originally as no more than a growth and 
survival factor for certain neuronal cells, within the last 50 
years, Levi-Montalcini’s students and disciples dispersed all 
over the world have been passing the torch of NGF research 
from generation to generation. 
    In conclusion, NGF2002 demonstrated highly graphically 
how NGF and its relatives, in addition to their neurotrophic 
activities, also exert important and often critical immunotrophic, 
epitheliotrophic, and inflammation-, allergy- and tissue repair-
associated activities. Paraphrasing Emily Dickinson’s poem 
The brain is wider than the sky, when Rita Levi-Montalcini 
discovered NGF more than 50 years ago, could she possibly 
have imagined that the NGF is wider than the neuron? Indeed, 
it is extremely rare for one scientist to contribute so much to 
the development of a research field, as she has done! 
    Arrivederci, the Modena NGF2002 Conference! Doubtlessly, 
many new findings on NGF will emerge in the next two years, 
and will further enrich Rita Levi-Montalcini’s Saga of the 
NGF.  
ACKNOWLEDGMENTS
Creative reading of the manuscript by Dr John Heuser is 
highly appreciated.
George N. Chaldakov
Invited Observer at the 7th International NGF 
and Related Molecules Conference
Medical University
Varna, Bulgaria
